Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
Oramed Pharmaceuticals said in a shareholder letter it will be added to the Russell 2000 and Russell 3000 indexes effective June 29, 2026. The company reported its Alpha Tau (DRTS) position is up about $128 million to ~$167 million (incl. warrants), and that its Scilex (SCLX) $99.5 million loan has been substantially repaid, with ~$43 million expected by Oct. 2026. Oramed also cited total cash and assets of about $270 million as of March 31, 2026.
How this was made
The 30-second read
Why it matters
The most tradable near-term element is the scheduled Russell 2000/3000 addition (June 29 open), which can affect flows/liquidity. The biotech-specific details (DRTS deal/trial updates) may support sentiment but are delivered via a shareholder letter rather than a fresh primary disclosure.
Market read
Traders may monitor ORMP for small-cap index flow effects around June 29, while biotech traders may watch DRTS for continued commercialization/trial momentum referenced in the letter.
What to watch
The letter’s most detailed figures are framed as ORMP’s investment economics (loan recoupment, position value) rather than new ORMP/SCLX/LFWD corporate guidance, which can limit near-term price follow-through.
Background
Oramed issued a CEO shareholder letter summarizing strategic portfolio developments, a Scilex loan repayment, and expected Russell index inclusion.
Ticker impact
Oramed’s CEO letter says ORMP will be added to the Russell 2000/3000 on June 29 and highlights a ~$270M cash/assets balance.
Mild positive bias near index-reconstitution with limited fundamental repricing unless investors treat the portfolio/loan recoup figures as incremental.
The article is a shareholder letter emphasizing expected index addition and previously described strategic transactions; it provides concrete figures but not a fresh earnings/guidance release.
Oramed highlights its Alpha Tau (DRTS) position, including a June 2026 U.S. commercialization partnership with Tolmar and milestone/equity terms.
Potential upward drift as investors price in commercialization and ongoing trial progress; volatility likely around biotech newsflow.
The letter contains multiple DRTS-related program and deal specifics, but it is still framed as a shareholder update rather than a standalone primary filing.
Oramed states its Scilex (SCLX) loan was substantially repaid and expects ~$43M by October 2026 plus an ongoing 4% royalty.
Limited direct impact on SCLX equity unless the market views it as signaling improved product/royalty cash flows; could still support sentiment.
The disclosure is from ORMP’s perspective (loan repayment/royalty economics) rather than a new SCLX corporate action or guidance update.
Oramed says Lifeward (LFWD) completed a March 2026 transaction and reports Q1 2026 progress including ~33% lower operating cash burn and +11% ReWalk sales.
Moderate positive sentiment effect; likely incremental rather than a major repricing catalyst.
The article references LFWD results reported in May 2026, so the incremental value is limited versus the underlying earnings already released.
Market effects
Biopharma/medtech investors may re-focus on oral drug-delivery and alpha-radiation platform commercialization timelines and trial progression.
Primarily U.S. small-cap index mechanics (Russell reconstitution) with potential spillover to biotech small/mid-cap liquidity.
Limited; the key items are U.S. index inclusion and U.S. commercialization/trial updates, with some international context (Israel/Japan approvals) mentioned.
Counterpoint
Index inclusion and portfolio appreciation narratives may already be anticipated; without new ORMP earnings/guidance, the market may discount the letter’s impact.
Key entities
- companyOramed Pharmaceuticals Inc.
Subject of the shareholder letter; highlights Russell index inclusion and balance-sheet/portfolio updates.
- companyAlpha Tau (DRTS)
Oramed’s highlighted position; letter cites Tolmar commercialization partnership and trial/data updates.
- companyScilex (SCLX)
Oramed’s loan counterparty; letter cites substantial loan repayment and ongoing royalty economics.
- companyLifeward (LFWD)
Oramed’s portfolio holding; letter cites Q1 2026 operational progress.
